A new trading day began on Friday, with Arcutis Biotherapeutics Inc (NASDAQ: ARQT) stock price down -9.56% from the previous day of trading, before settling in for the closing price of $15.27. ARQT’s price has ranged from $3.11 to $16.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 379.27% over the last five years. Meanwhile, its annual earnings per share averaged 64.32%. With a float of $102.98 million, this company’s outstanding shares have now reached $117.00 million.
The firm has a total of 296 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.02%, while institutional ownership is 103.05%. The most recent insider transaction that took place on Jan 02 ’25, was worth 146,714. In this transaction Director of this company sold 10,000 shares at a rate of $14.67, taking the stock ownership to the 151,944 shares. Before that another transaction happened on Jan 02 ’25, when Company’s Director proposed sale 10,000 for $14.67, making the entire transaction worth $146,714.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.32% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Here are Arcutis Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 1.97 million was lower than the volume posted last year of 2.05 million. As of the previous 9 days, the stock’s Stochastic %D was 42.39%. Additionally, its Average True Range was 1.01.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 70.75%, which indicates a significant increase from 32.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.95% in the past 14 days, which was higher than the 68.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.06, while its 200-day Moving Average is $10.10. Now, the first resistance to watch is $14.68. This is followed by the second major resistance level at $15.55. The third major resistance level sits at $16.04. If the price goes on to break the first support level at $13.32, it is likely to go to the next support level at $12.83. Should the price break the second support level, the third support level stands at $11.96.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
With a market capitalization of 1.62 billion, the company has a total of 117,045K Shares Outstanding. Currently, annual sales are 59,610 K while annual income is -262,140 K. The company’s previous quarter sales were 44,760 K while its latest quarter income was -41,540 K.
